You are here: Industry Insights > Sanofi

News List

Sanofi plans to ‘a(chǎn)irlift’ flu vaccine into UK in no-deal event pharmatimes
March 27, 2019
In the wake of Brexit and the event of a no-deal exit from the European Union, French pharmaceutical giant Sanofi has said it could potentially airlift its flu vaccine into the UK.
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes expressbpd
March 26, 2019
The setback comes as Sanofi works to revive declining sales from its diabetes division and faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.
FDA stiff-arms Sanofi and Lexicon's Type 1 diabetes hopeful Zynquista fiercepharma
March 23, 2019
The FDA stiff-armed?Sanofi and Lexicon's diabetes drug Zynquista on Friday, darkening the companies' hopes of launching the drug for Type 1 diabetes this year.
EU regulators expand Praluent’s label pharmatimes
March 19, 2019
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Regeneron/Sanofi wins US approval for expanded use of skin drug expressbpd
March 14, 2019
The US Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17
Sanofi, Regeneron's Dupixent gains expanded approval in US for certain adolescents with atopic dermatitis firstwordpharma
March 12, 2019
Sanofi and Regeneron Pharmaceuticals on Monday announced that the FDA has expanded approval of Dupixent?(dupilumab) to include use in adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis that is not adequately controlled with topical
FDA advisory panel recommends against use of Sanofi's dengue vaccine Dengvaxia in adults biospectrumasia
March 11, 2019
An FDA advisory committee voted 7-6, with one abstention, that data provided by Sanofi do not support the effectiveness of?the drugmaker's?dengue vaccine Dengvaxia in patients aged nine to 45?years?living in endemic areas who were previously diagnosed wit
Now that Lilly has a cheaper generic Humalog, will Novo Nordisk and Sanofi follow? fiercepharma
March 08, 2019
Caught by an outcry over high insulin prices, Eli Lilly recently unveiled an authorized generic version of its Humalog insulin at half the price of the original brand.
Lilly to sell generic Humalog insulin at half price pharmaphorum
March 07, 2019
Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand.
Sanofi, boosted by partnerships, lays out connected tech ambitions in diabetes fiercepharma
March 07, 2019
Technology solutions are key to the future of diabetes—especially personalized, "smart" connected tech.